The curious case of type I interferon signaling in cancer

被引:0
|
作者
Chhipa, Abu Sufiyan [1 ,2 ]
Boscaro, Valentina [2 ]
Gallicchio, Margherita [2 ]
Patel, Snehal [1 ]
机构
[1] Nirma Univ, Inst Pharm, Dept Pharmacol, Ahmadabad 382481, India
[2] Univ Turin, Dept Drug Sci & Technol, I-10125 Turin, Italy
来源
关键词
Cancer; IFN-1; TME; STAT; uSTAT; ISGF3; uISGF3; MESENCHYMAL STEM-CELLS; DEPENDENT ANTITUMOR IMMUNITY; TRAIL-INDUCED APOPTOSIS; BREAST-CANCER; GENE-EXPRESSION; CYTOSOLIC DNA; IFN-GAMMA; TUMOR MICROENVIRONMENT; DENDRITIC CELLS; STROMAL CELLS;
D O I
10.1016/j.bbcan.2024.189204
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytokines are the crucial signaling proteins that mediate the crosstalks between the cells of tumor microenvironment (TME). Interferon-1 (IFN-1) are the important cytokines that are widely known for their tumor suppressive roles comprising of cancer cell intrinsic and extrinsic mechanisms. Despite having known antitumor effects, IFN-1 are also reported to have tumor promoting functions under varying circumstances. This dichotomy in the functions of IFN-1 is largely attributed to the acute and chronic activation of IFN-1 signaling in TME. The chronic activation of IFN-1 signaling in tumor cells results in altered stimulation of downstream pathways that result in the expression of tumor promoting proteins, while the acute IFN-1 signaling activation maintains its tumor inhibiting functions. In the present review, we have discussed the antiand pro-tumor actions of IFN-1 signaling under acute and chronic IFN-1 signaling activation. We have also discussed the downstream changes in signaling components that result in tumor supportive functions of a constitutive IFN-1 signaling. We have further discussed the possible strategies to overcome the detrimental effects of chronic IFN-1 pathway activation and to successfully employ IFN-1 for their beneficial anti-tumor effects.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Type I interferon signaling promotes radioresistance in head and neck cancer
    Zenga, Joseph
    Awan, Musaddiq J.
    Frei, Anne
    Massey, Becky
    Bruening, Jennifer
    Shukla, Monica
    Sharma, Guru Prasad
    Shreenivas, Aditya
    Wong, Stuart J.
    Zimmermann, Michael T.
    Mathison, Angela J.
    Himburg, Heather A.
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (05) : 2535 - 2543
  • [2] Type I and II interferon signaling in colorectal cancer liver metastasis
    Moedl, Bernadette
    Moritsch, Stefan
    Zwolanek, Daniela
    Eferl, Robert
    CYTOKINE, 2023, 161
  • [3] Type I Interferon at the Interface of Antiviral Immunity and Immune Regulation: The Curious Case of HIV-1
    Boasso, Adriano
    SCIENTIFICA, 2013, 2013
  • [4] Type I interferon and cancer
    Holicek, Peter
    Guilbaud, Emma
    Klapp, Vanessa
    Truxova, Iva
    Spisek, Radek
    Galluzzi, Lorenzo
    Fucikova, Jitka
    IMMUNOLOGICAL REVIEWS, 2024, 321 (01) : 115 - 127
  • [5] Enhanced type I interferon signaling in dermatomyositis
    Somani, A.
    Karnik, P.
    McCormick, T. S.
    Cooper, K. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S14 - S14
  • [6] Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
    Antonella Sistigu
    Takahiro Yamazaki
    Erika Vacchelli
    Kariman Chaba
    David P Enot
    Julien Adam
    Ilio Vitale
    Aicha Goubar
    Elisa E Baracco
    Catarina Remédios
    Laetitia Fend
    Dalil Hannani
    Laetitia Aymeric
    Yuting Ma
    Mireia Niso-Santano
    Oliver Kepp
    Joachim L Schultze
    Thomas Tüting
    Filippo Belardelli
    Laura Bracci
    Valentina La Sorsa
    Giovanna Ziccheddu
    Paola Sestili
    Francesca Urbani
    Mauro Delorenzi
    Magali Lacroix-Triki
    Virginie Quidville
    Rosa Conforti
    Jean-Philippe Spano
    Lajos Pusztai
    Vichnou Poirier-Colame
    Suzette Delaloge
    Frederique Penault-Llorca
    Sylvain Ladoire
    Laurent Arnould
    Joanna Cyrta
    Marie-Charlotte Dessoliers
    Alexander Eggermont
    Marco E Bianchi
    Mikael Pittet
    Camilla Engblom
    Christina Pfirschke
    Xavier Préville
    Gilles Uzè
    Robert D Schreiber
    Melvyn T Chow
    Mark J Smyth
    Enrico Proietti
    Fabrice André
    Guido Kroemer
    Nature Medicine, 2014, 20 : 1301 - 1309
  • [7] Progesterone receptor inhibition of efficient type I interferon signaling in breast cancer
    Walter, Katherine Rose
    Goodman, Merit
    Hagan, Christy
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Designing a Type I Interferon Signaling Phagosome
    Blander, J. Magarian
    IMMUNITY, 2012, 37 (06) : 947 - 949
  • [9] Induction of DNA Damage in Ovarian Cancer Induces Type I Interferon Signaling
    Bolland, Danielle E.
    Tan, Yee Sun
    Hao, Yuning
    Hacker, Kari E.
    Tan, Lijun
    Xie, Yuying
    Lei, Yu
    McLean, Karen
    FASEB JOURNAL, 2018, 32 (01):
  • [10] Differential Regulation of Type I and Type III Interferon Signaling
    Stanifer, Megan L.
    Pervolaraki, Kalliopi
    Boulant, Steeve
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (06)